https://mindmedicinelaw.com/briefing/ketamine-s-metabolic-safety-in-mood-disorder-treatment-20260821-34537The Psychedelic Journalen2026-08-22T22:04:57.064670+00:00Ketamine's Metabolic Safety in Mood Disorder Treatmentketamine, appetite, treatment-resistant mood disorders, metabolic safety, clinical trials, depression treatment, bipolar disorder, psychiatric medication, Visual Analog Scales, Simplified Nutritional Appetite Questionnairehttps://mindmedicinelaw.com/briefing/triptally-a-new-tool-for-estimating-psychedelic-therapy-costs-20260821-34523The Psychedelic Journalen2026-08-22T22:04:08.263473+00:00TripTally: A New Tool for Estimating Psychedelic Therapy Costspsychedelic therapy, cost estimation, TripTally, labor costs, FDA approval, economic planning, resource allocation, clinical trialshttps://mindmedicinelaw.com/briefing/cb1-allosteric-modulation-therapeutic-potential-risks-20260821-34538The Psychedelic Journalen2026-08-22T22:04:00.940033+00:00CB1 Allosteric Modulation: Therapeutic Potential & RisksCB1 allosteric modulators, therapeutic potential, misuse liability, pain relief, addiction treatment, THC alternatives, neuropathic pain, pharmacological profiles, endocannabinoid systemhttps://mindmedicinelaw.com/briefing/enhancing-causal-inference-in-psychedelic-trials-20260821-34524The Psychedelic Journalen2026-08-22T22:03:53.293437+00:00Enhancing Causal Inference in Psychedelic Trialspsychedelic research, clinical trials, causal inference, pretreatment expectancy, double-blind procedure, active placebo, crossover trial, ethical considerationshttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-program-early-outcomes-and-implications-20260821-34766The Psychedelic Journalen2026-08-22T22:03:36.463931+00:00Oregon's Psilocybin Program: Early Outcomes and ImplicationsOregon psilocybin program, psychedelic therapy, psilocybin treatment, mental health, state-sanctioned psychedelics, Oregon Health Authority, Measure 109, regulated psychedelic use, therapeutic potential, psilocybin policyhttps://mindmedicinelaw.com/briefing/mdma-for-neuropathic-pain-calls-for-phase-2-3-trials-20260821-34511The Psychedelic Journalen2026-08-22T15:05:55.401104+00:00MDMA for Neuropathic Pain: Calls for Phase 2/3 TrialsMDMA, neuropathic pain, clinical trials, neuroplasticity, pain management, Phase 2/3 trials, neurobiology, pain pathways, BDNF, safety considerationshttps://mindmedicinelaw.com/briefing/ohsu-psilocybin-study-implications-for-anxiety-depression-ptsd-20260821-34605The Psychedelic Journalen2026-08-22T15:05:45.199479+00:00OHSU Psilocybin Study: Implications for Anxiety, Depression, PTSDOHSU psilocybin study, psilocybin anxiety treatment, depression and psilocybin, PTSD psychedelic therapy, psilocybin clinical trials, mental health psychedelics, psilocybin regulatory implications, psilocybin serotonin interactionhttps://mindmedicinelaw.com/briefing/mdma-for-neuropathic-pain-clinical-trial-blueprint-20260821-34510The Psychedelic Journalen2026-08-22T15:05:34.173932+00:00MDMA for Neuropathic Pain: Clinical Trial BlueprintMDMA, neuropathic pain, clinical trials, neuroplasticity, pain management, monoamine transporters, oxytocin, BDNF, safety considerations, active placebohttps://mindmedicinelaw.com/briefing/jama-study-evaluates-oregon-s-psilocybin-services-model-20260821-34522The Psychedelic Journalen2026-08-22T15:05:24.312748+00:00JAMA Study Evaluates Oregon's Psilocybin Services ModelOregon psilocybin model, JAMA study, psychedelic-assisted therapy, state-regulated psilocybin, clinical trials, policy implications, psilocybin risks, mental health, therapeutic efficacy, regulatory frameworkshttps://mindmedicinelaw.com/briefing/trump-s-executive-order-boosts-psychedelic-research-20260821-34608The Psychedelic Journalen2026-08-22T15:05:00.481939+00:00Trump's Executive Order Boosts Psychedelic Researchpsychedelic research, executive order, Trump, clinical trials, mental health, FDA, NIH, psilocybin, MDMA, public health policyhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-for-refractory-behavioral-conditions-20260820-34490The Psychedelic Journalen2026-08-22T22:04:28.391010+00:00Psilocybin's Potential for Refractory Behavioral Conditionspsilocybin, mental health treatment, serotonin receptors, regulatory constraints, federal funding, biosynthetic production, psychotherapy integration, clinical trials, substance use disorders, neuroplasticityhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-hippocampal-sharp-wave-ripples-20260820-34525The Psychedelic Journalen2026-08-22T22:04:15.845467+00:00Psilocybin's Impact on Hippocampal Sharp Wave Ripplespsilocybin, hippocampal sharp wave ripples, memory consolidation, neural plasticity, serotonergic receptors, depression treatment, anxiety treatment, sleep architecture, therapeutic applications, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-alters-personality-in-alcohol-use-disorder-20260820-34765The Psychedelic Journalen2026-08-22T22:03:45.474392+00:00Psilocybin Therapy Alters Personality in Alcohol Use Disorderpsilocybin therapy, alcohol use disorder, clinical trial, personality changes, psychedelic research, mental health treatment, serotonin receptors, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/psilocybin-microdosing-systematic-review-highlights-gaps-20260819-34491The Psychedelic Journalen2026-08-22T22:04:47.986376+00:00Psilocybin Microdosing: Systematic Review Highlights Gapspsilocybin microdosing, systematic review, randomized controlled trials, mental health, safety profile, dosing protocols, adverse events, clinical practice, policy-making, conflicts of interesthttps://mindmedicinelaw.com/briefing/trump-s-psychedelic-plan-for-veterans-policy-implications-20260819-34767The Psychedelic Journalen2026-08-22T22:04:38.281745+00:00Trump's Psychedelic Plan for Veterans: Policy Implicationspsychedelic therapies, veterans mental health, Trump policy, PTSD treatment, federal drug policy, FDA psychedelic research, MDMA therapy, psilocybin research, mental health policy, veterans healthcarehttps://mindmedicinelaw.com/briefing/psilocybin-alters-brain-burst-firing-via-5-ht2a-circuits-20260819-34527The Psychedelic Journalen2026-08-22T15:06:07.183479+00:00Psilocybin Alters Brain Burst Firing via 5-HT2A Circuitspsilocybin, 5-HT2A receptor, burst firing, brain circuit dynamics, psychedelic research, therapeutic mechanisms, neuroscience, clinical trialshttps://mindmedicinelaw.com/briefing/oregon-psilocybin-services-safety-and-mental-health-outcomes-20260819-34492The Psychedelic Journalen2026-08-22T15:05:13.224107+00:00Oregon Psilocybin Services: Safety and Mental Health OutcomesOregon psilocybin services, mental health outcomes, psilocybin therapy, state-regulated psychedelics, depression and anxiety treatment, psilocybin safety, therapeutic benefits of psilocybin, psychedelic research, policy implications, clinical practicehttps://mindmedicinelaw.com/briefing/esketamine-routes-in-post-op-hyperalgesia-trial-insights-20260818-34426The Psychedelic Journalen2026-08-21T22:06:54.294469+00:00Esketamine Routes in Post-Op Hyperalgesia: Trial Insightsesketamine, postoperative hyperalgesia, elderly patients, pain management, clinical trials, surgical settings, administration routes, opioid alternatives, psychedelic research, neurosciencehttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-brain-dynamics-in-fmri-study-20260818-34424The Psychedelic Journalen2026-08-21T22:06:41.152630+00:00Ketamine's Impact on Brain Dynamics in fMRI Studyketamine, fMRI, rumination, brain dynamics, glutamatergic mechanisms, antidepressant, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/long-term-safety-of-ketamine-in-treatment-resistant-depression-20260817-34553The Psychedelic Journalen2026-08-22T15:06:16.592669+00:00Long-term Safety of Ketamine in Treatment-resistant Depressionketamine, esketamine, treatment-resistant depression, long-term safety, systematic review, clinical trials, neurocognitive effects, iatrogenic addiction, organ toxicity, transient side effectshttps://mindmedicinelaw.com/briefing/iv-ketamine-for-adolescent-depression-efficacy-and-safety-20260815-34554The Psychedelic Journalen2026-08-22T15:06:40.027945+00:00IV Ketamine for Adolescent Depression: Efficacy and Safetyintravenous ketamine, adolescent depression, major depressive disorder, treatment-resistant depression, meta-analysis, antidepressant effects, clinical trials, safety and efficacy, psychiatric treatment, neurosciencehttps://mindmedicinelaw.com/briefing/ai-s-role-in-psychedelic-therapy-relational-competence-issues-20260814-34497The Psychedelic Journalen2026-08-22T15:06:50.704495+00:00AI's Role in Psychedelic Therapy: Relational Competence IssuesAI in psychedelic therapy, relational competence, facilitator training, policy challenges, therapeutic alliance, accreditation infrastructure, equity in therapy, psychedelic trials, AI tools in therapy, ketamine-assisted psychotherapyhttps://mindmedicinelaw.com/briefing/lsd-therapy-research-new-insights-and-implications-20260814-34325The Psychedelic Journalen2026-08-21T15:05:08.261675+00:00LSD Therapy Research: New Insights and ImplicationsLSD therapy, psychedelic research, mental health treatment, clinical trials, serotonin receptors, policy implications, therapeutic benefits, psychedelic-assisted therapies, regulatory changes, adverse effects